Wealth Enhancement Advisory Services LLC Purchases 5,000 Shares of Oramed Pharmaceuticals Inc. $ORMP

Wealth Enhancement Advisory Services LLC lifted its position in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) by 36.2% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 18,799 shares of the biotechnology company’s stock after purchasing an additional 5,000 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Oramed Pharmaceuticals were worth $41,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. N.E.W. Advisory Services LLC raised its holdings in shares of Oramed Pharmaceuticals by 52.9% during the 1st quarter. N.E.W. Advisory Services LLC now owns 18,900 shares of the biotechnology company’s stock worth $40,000 after acquiring an additional 6,540 shares in the last quarter. Jane Street Group LLC raised its holdings in shares of Oramed Pharmaceuticals by 35.3% during the 1st quarter. Jane Street Group LLC now owns 67,173 shares of the biotechnology company’s stock worth $144,000 after acquiring an additional 17,510 shares in the last quarter. Peapod Lane Capital LLC raised its stake in Oramed Pharmaceuticals by 11.0% during the first quarter. Peapod Lane Capital LLC now owns 252,224 shares of the biotechnology company’s stock valued at $540,000 after purchasing an additional 24,985 shares in the last quarter. Finally, BML Capital Management LLC raised its stake in Oramed Pharmaceuticals by 14.3% during the first quarter. BML Capital Management LLC now owns 3,020,748 shares of the biotechnology company’s stock valued at $6,464,000 after purchasing an additional 376,841 shares in the last quarter. Institutional investors own 12.73% of the company’s stock.

Oramed Pharmaceuticals Trading Up 1.7%

Shares of ORMP opened at $2.41 on Monday. Oramed Pharmaceuticals Inc. has a twelve month low of $1.82 and a twelve month high of $3.09. The company has a market cap of $98.81 million, a P/E ratio of -6.89 and a beta of 1.62. The company’s fifty day simple moving average is $2.28 and its 200-day simple moving average is $2.22.

Oramed Pharmaceuticals (NASDAQ:ORMP) last announced its earnings results on Thursday, August 14th. The biotechnology company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.01). Analysts predict that Oramed Pharmaceuticals Inc. will post -0.03 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Oramed Pharmaceuticals in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Oramed Pharmaceuticals presently has a consensus rating of “Sell”.

Oramed Pharmaceuticals Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.